Abstract | BACKGROUND: The etonogestrel subdermal implant received US Food and Drug Administration approval in 2006. Menstrual changes represent a common reason why recipients of this implant request early implant removal. STUDY DESIGN: Retrospective review of medical records of 155 patients with placement of this implant at Mayo Clinic in Rochester, Minnesota, and medical literature review. RESULTS: In 151 patients (97.4%), this implant was placed for contraception. Sixty-four patients (41.3%) contacted a health care provider about implant-related issues after insertion, including 39 (25.2%) for abnormal bleeding. Mean body mass index (BMI) was 28.5, higher than prior studies of implant-related bleeding. Implant removal rate was 25.2% (mean interval, 9.8 months), with 14.8% requesting removal for bleeding changes. No insertion or postinsertion complications or contraceptive failures were found. CONCLUSIONS:
|
Authors | Petra M Casey, Margaret E Long, Mary L Marnach, Jessica E Bury |
Journal | Contraception
(Contraception)
Vol. 83
Issue 5
Pg. 426-30
(May 2011)
ISSN: 1879-0518 [Electronic] United States |
PMID | 21477684
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- Contraceptive Agents, Female
- Drug Implants
- etonogestrel
- Desogestrel
|
Topics |
- Adolescent
- Adult
- Body Mass Index
- Contraceptive Agents, Female
(administration & dosage, adverse effects)
- Desogestrel
(administration & dosage, adverse effects)
- Device Removal
- Drug Implants
(administration & dosage, adverse effects)
- Female
- Humans
- Metrorrhagia
(chemically induced)
- Minnesota
- Pregnancy
- Retrospective Studies
- Young Adult
|